Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(3.45)
# 941
Out of 5,090 analysts
86
Total ratings
43.33%
Success rate
6.9%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Buy | $60 | $26.57 | +125.82% | 1 | Dec 3, 2025 | |
| TRAW Traws Pharma | Initiates: Buy | $8 | $2.29 | +249.34% | 1 | Dec 3, 2025 | |
| CRDL Cardiol Therapeutics | Reiterates: Buy | $9 | $1.05 | +757.14% | 2 | Dec 1, 2025 | |
| CRMD CorMedix | Maintains: Buy | $17 → $18 | $10.56 | +70.45% | 4 | Nov 13, 2025 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $44 → $46 | $47.91 | -3.99% | 7 | Nov 7, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $10 | $6.51 | +53.61% | 3 | Nov 7, 2025 | |
| INDV Indivior | Maintains: Buy | $28 → $35 | $35.12 | -0.34% | 2 | Oct 30, 2025 | |
| RANI Rani Therapeutics Holdings | Assumes: Buy | $11 | $1.59 | +591.82% | 3 | Oct 21, 2025 | |
| OMER Omeros | Maintains: Buy | $9 → $20 | $10.85 | +84.33% | 3 | Oct 15, 2025 | |
| MNKD MannKind | Reiterates: Buy | $11 | $5.68 | +93.66% | 6 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.36 | +635.29% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $81.77 | +47.98% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $9.00 | +100.00% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.93 | +63.93% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.62 | +159.74% | 2 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $6.28 | +91.08% | 3 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.97 | +227.46% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.40 | +191.67% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $29 | $6.39 | +353.83% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $14.60 | +36.99% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $8.71 | +198.51% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.31 | +358.02% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $5 | $2.68 | +86.57% | 2 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $13.47 | +55.90% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.99 | +406.64% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.31 | +2,492.35% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $11.90 | +34.45% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $19.15 | +2,275.98% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $21.69 | +172.01% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $169.70 | +6.07% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.49 | +8,735.34% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $29.52 | +8.40% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.20 | +1,833,233.33% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $9.55 | +423.56% | 1 | Jul 12, 2018 |
Pelthos Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $60
Current: $26.57
Upside: +125.82%
Traws Pharma
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $2.29
Upside: +249.34%
Cardiol Therapeutics
Dec 1, 2025
Reiterates: Buy
Price Target: $9
Current: $1.05
Upside: +757.14%
CorMedix
Nov 13, 2025
Maintains: Buy
Price Target: $17 → $18
Current: $10.56
Upside: +70.45%
Collegium Pharmaceutical
Nov 7, 2025
Maintains: Buy
Price Target: $44 → $46
Current: $47.91
Upside: -3.99%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Buy
Price Target: $10
Current: $6.51
Upside: +53.61%
Indivior
Oct 30, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $35.12
Upside: -0.34%
Rani Therapeutics Holdings
Oct 21, 2025
Assumes: Buy
Price Target: $11
Current: $1.59
Upside: +591.82%
Omeros
Oct 15, 2025
Maintains: Buy
Price Target: $9 → $20
Current: $10.85
Upside: +84.33%
MannKind
Oct 13, 2025
Reiterates: Buy
Price Target: $11
Current: $5.68
Upside: +93.66%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.36
Upside: +635.29%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $81.77
Upside: +47.98%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $9.00
Upside: +100.00%
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $7.93
Upside: +63.93%
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $4.62
Upside: +159.74%
Aug 20, 2025
Reiterates: Buy
Price Target: $12
Current: $6.28
Upside: +91.08%
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $3.97
Upside: +227.46%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.40
Upside: +191.67%
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $6.39
Upside: +353.83%
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $14.60
Upside: +36.99%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $8.71
Upside: +198.51%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.31
Upside: +358.02%
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $2.68
Upside: +86.57%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $13.47
Upside: +55.90%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.99
Upside: +406.64%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.31
Upside: +2,492.35%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $11.90
Upside: +34.45%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $19.15
Upside: +2,275.98%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $21.69
Upside: +172.01%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $169.70
Upside: +6.07%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.49
Upside: +8,735.34%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $29.52
Upside: +8.40%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.20
Upside: +1,833,233.33%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $9.55
Upside: +423.56%